ROS1 and non-small cell lung carcinoma: Entrectinib, an FDA approved drug for the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors (Ardini et al., 2016; Russo et al., 2016), has been identified in this study as an inhibitor of DENV, hNV, and HCV.